ClinicalTrials.gg
RecruitingNCT05785546BPIP-Score MNMUpdated Mar 19, 2025

Elaboration of a Pronostic Score of Changes on Wheelchair's Seating System

An observational study in Neuromuscular Diseases, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
368
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris — 3 open to participants now, 3 under way, none of them phase 3. Neuromuscular Diseases · Assistance Publique - Hôpitaux de Paris.

Started
2025
the only one that year
Observational
6 of 10
2 open now
Registered
8th of 10
by date

Among the 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2025, is one of 6 observational ones, and was the 8th registered.

Neuromuscular Diseases

361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.

Browse Neuromuscular Diseases studies →

Open to participants now

3 of the 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Development and validation study of a prognostic score - study of prognostic performance by a prospective longitudinal multicenter cohort spread over 8 centers: 4 for the development cohort and 4 for the validation cohort).

Read the detailed description

Progressive muscle weakness in neuromuscular diseases leads to motor disabilities leading to permanentfull-time wheelchair use. This is the case for infantile spinal muscular atrophy type II (SMA II), where people are dependent on a permanent sitting position from early childhood, at 2 years of age, or for Duchenne muscular dystrophy, when they lose their ability to walk around 10 years without corticosteroid therapy or around 13 years with treatment. These wheelchair users, weakened by the disease, are subject to musculotendinous retractions, osteo-articular stiffness, spinal deformities and pain. In addition, they use the wheelchair on a daily basis, on average 12 hours a day, whose permanent sitting position also conditions the performance of achieving life habits.

The analysis of the static and dynamic seated postural installation in the wheelchair makes it possible to avoid harmful consequences on the health and quality of life of users on a daily basis. When performed early enough, regularly and optimally, it also contributes to the prevention of complications.

In France, these assessments are carried out by occupational therapists, accompanied by doctors of Physical Medicine and Rehabilitation.

The weakness of the literature in this area and the absence of recommendations do not allow the user or any health professional to identify the need and the level of urgency to benefit from a dedicated consultation.

Faced with this observation, the development of a prognostic score for a change in positioning in the wheelchair, based on a prospective multicenter cohort and its validation on an external prospective cohort, will allow any healthcare professional to guide the user to a necessary positioning consultation. The hypothesis is that this score has discriminating qualities and that it is calibrated to predict a change in the seat of the RF and therefore the need to reassess the seated postural installation.

03

Conditions studied

  • Neuromuscular Diseases

Keywords

  • Neuromuscular Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Having a neuromuscular disease such as Duchenne Muscular Dystrophy or Infantile Spinal Muscular Atrophy type II.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female over the age of 18
  • Daily wheelchair user (more than 4 hours per day)
  • Having a neuromuscular disease such as Duchenne Muscular Dystrophy or Infantile Spinal Muscular Atrophy type II
  • Accompanied by an identified medical equipment provider, able to respond to the recommendations of the clinical team
  • Patient informed and having signed consent.

Exclusion criteria

Exclusion Criteria:

  • Person who already has a seat change or FR prescription at the time of inclusion
  • Having undergone surgery less than 1 year ago or a fracture
  • Pregnant or breastfeeding women
  • Patient under guardianship or curatorship.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
368 participants (estimated)
Patient registry
No

Groups and cohorts

  • development cohort

    Neuromuscular diseases

    Other: usual care

  • validation cohort

    Neuromuscular diseases

    Other: usual care

Interventions

  • Otherusual care

    For each cohort, the patient is seen at least twice, during annual visits in multidisciplinary consultation.

06

What researchers measure

Primary outcomes

  1. Change in the seating system of the user's wheelchair

    Any change in the seating system of the user's wheelchair within 12 months will be noted. A change in the seating system is defined by the occurrence of at least one of these situations: * one or more seat/back adjustments: depth, width, height * addition/removal of postural elements * replacement of the cushion, or backrest or headrest * Use of electric functions of the wheelchair or on-board standing * modification of control device of the WC.

    Time frame: through study completion, to 12 months

Secondary outcomes

  1. Seated Postural Control Measure (SPCM)

    Seated Postural Control Measure (SPCM) is an instrument for the clinical assessment of seated postural control in adult clients using a locomotion aid. It therefore allows the evaluation of the two variables in inherent to postural control seated, i.e. the alignment of body segments and the influence between movement and posture. It also helps to assess changes of seated postural control due to the evolution over time or to an intervention of a adaptation of the sitting posture.

    Time frame: at baseline and 12 months

  2. Pain Visual Analogue Scale

    To assess pain, the investigators will use a Visual Analog Scale (0-10).

    Time frame: at baseline and 12 months

  3. Pressure ulcer topography (stage and location )

    International NPUAP/EPUAP Pressure injury classification system

    Time frame: at baseline and 12 months

  4. Comfort perception scale (Visual Analogue Scale)

    Visual Analog Scale (0-10) will be used to assess comfort of patients.

    Time frame: at baseline and 12 months

  5. Postural stability perception scale (in antero-posterior and lateral stability)

    self-questionnaire will be used.

    Time frame: at baseline and 12 months

  6. adverse event

    Semi-structured interview following the identification of an adverse event in wheelchair by the user, within 12 months after inclusion. explain or understand the identification or not of an adverse event in wheelchair and its escalation to the clinical team, by the user.

    Time frame: through study completion, an average of 12 month

07

Study locations

1 of 1 sites recruiting
  • New technology Platform department, Raymond Poincaré Hospital, APHP
    Garches, 92380, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2028, 36 months after the start.

Of 64 non-industry observational studies under Neuromuscular Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 114. This study's planned 36 months is close to that.

Counting every sponsor, half of 70 studies reached it within 37 months; a quarter within 12 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2023
First posted
Mar 27, 2023
StartActual
Feb 19, 2025
Primary completionEst.
Feb 2028
CompletionEst.
Mar 2028
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05785546
Responsible party
Sponsor
First posted
Mar 27, 2023
Start date
Feb 19, 2025
Primary completion
Feb 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Mar 19, 2025

Study contacts

Samuel Pouplin, PhD
Contact
samuel.pouplin@aphp.fr
+ 33 (0)1.47.10.70.61
Samuel Pouplin, PhD
principal investigator · New technology Platform department, Raymond Poincaré Hospital, APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion